- Home
- GRNT vs AUPH Comparison
GRNT vs AUPH Comparison
Compare GRNT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRNT | AUPH |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.9M | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | GRNT | AUPH |
|---|---|---|
| Price | $4.95 | $15.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $8.00 | ★ $17.25 |
| AVG Volume (30 Days) | 585.2K | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.29 | ★ 0.55 |
| Revenue | ★ $427,828,000.00 | $265,808,000.00 |
| Revenue This Year | $34.64 | $21.22 |
| Revenue Next Year | $8.76 | $15.40 |
| P/E Ratio | ★ $17.56 | $28.81 |
| Revenue Growth | 19.33 | ★ 20.62 |
| 52 Week Low | $4.52 | $6.55 |
| 52 Week High | $7.00 | $16.48 |
Technical Indicators
Market Signals| Indicator | GRNT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 57.76 |
| Support Level | $5.14 | $15.15 |
| Resistance Level | $5.42 | $16.03 |
| Average True Range (ATR) | 0.17 | 0.50 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 10.34 | 57.02 |
Price Performance
Historical ComparisonAbout GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.